The Mundipharma network of independent associated companies has built a portfolio through strong business development and partnering skills.
Our partners are confident that we have the resources to help them take their products forward in a competitive marketplace.
By working together, we combine our expertise and commitment to optimise market potential and improve treatment options that could benefit millions of patients.
Current collaborations within Mundipharma independent associated companies network
Horizon Pharma [Nitec Pharma AG] for Lodotra® (modified-release prednisone), a programmed-release formulation licensed for rheumatoid arthritis and associated morning stiffness.
SkyePharma Plc for flutiform® (fluticasone/formoterol), a combination therapy in development for asthma.
SkyePharma Plc for Depocyte® (liposomal cytabine), a sustained-release formulation licensed for lymphomatous meningitis.
BioCryst Pharmaceuticals for forodesine hydrochloride, an inhibitor of the enzyme PNP (purine nucleoside phosphorylase) in development for T-cell lymphomas.
Astellas Pharma for Levact▼®/Ribomustin®/Ribovact® (bendamustine), a novel chemotherapy agent licensed for certain types of multiple myeloma, chronic lymphocytic leukaemia (CLL) and indolent non-Hodgkin’s lymphoma.
Allos Therapeutics Inc for Folotyn® (pralatrexate injection), a novel anti-folate inhibitor in development for peripheral T-cell lymphoma.
Mundipharma Medical Company has secured a distribution license from Celltrion Healthcare Hungary Kft for Remsima®▼ in Germany, Italy, UK, Netherlands, Belgium and Luxembourg